Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 948 clinical trials
A Phase 2, Open-label, Single Arm, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 (Lisocabtagene Maraleucel) in Adult Subjects With High-risk, Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good …

follicular lymphoma
marginal zone lymphoma
hodgkin's disease
fludarabine
cyclophosphamide
  • 27 views
  • 15 Sep, 2022
  • 30 locations
An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after

cancer
hematologic malignancy
follicular lymphoma
diffuse large b-cell lymphoma
hodgkin's disease
  • 145 views
  • 19 Sep, 2022
  • 12 locations
  • 0 views
  • 21 Sep, 2022
  • 6 locations
An Open-Label, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of RO7227166 (a CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of RO7227166 in participants with relapsed/refractory Non-Hodgkin's Lymphoma

cancer
b-cell lymphoma
hodgkin's disease
non-hodgkin's lymphoma refractory
obinutuzumab
  • 10 views
  • 22 Sep, 2022
  • 7 locations
A Phase I, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed OR Refractory Non-Hodgkin Lymphomas (R/R NHL).

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

hodgkin's disease
neutrophil count
blood transfusion
rituximab
  • 77 views
  • 22 Sep, 2022
  • 14 locations
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

leukemia
gilbert's syndrome
chronic lymphocytic leukemia
neutrophil count
platelet count
  • 25 views
  • 04 Oct, 2022
  • 17 locations
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To

lymphoma
multiple myeloma
measurable disease
primary cancer
dexamethasone
  • 31 views
  • 04 Oct, 2022
  • 13 locations
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To

lymphoma
multiple myeloma
  • 162 views
  • 04 Oct, 2022
  • 13 locations
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

renal function
chronic lymphocytic leukemia refractory
venetoclax
btk inhibitor
anemia
  • 188 views
  • 04 Oct, 2022
  • 59 locations
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE)

(RIPC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines.

  • 0 views
  • 04 Oct, 2022
  • 4 locations